Ekspresija matriks metaloproteinaza 2, 7 i 9 kod bolesnika sa kolorektalnim karcinomom

  • Elena Kostova Department of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss.Cyril and Methodius University
  • Maja Slaninka - Miceska Department of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
  • Nikola Labacevski Department of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
  • Krume Jakovski Department of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
  • Jasmina Trojachanec Department of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
  • Emilija Atanasovska Department of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
  • Vlado Janevski Digestive Surgery Clinic, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
  • Rubens Jovanovik Department of Pathology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
  • Vesna Janevska Department of Pathology, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia
DOI: https://doi.org/10.2298/3149
Ključne reči: colorectal neoplasms||, ||kolorektalne neoplazme, matrix metalloproteinases||, ||matriks metaloproteinaze, neoplasm staging||, ||neoplazme, određivanje stadijuma, immunohistochemistry||, ||imunohistohemija, sensitivity and specificity||, ||osetljivost i specifičnost,

Sažetak


Uvod/Cilj. Smatra se da matriks metaloproteinaze (MMPs) igraju ključnu ulogu u procesima tumorske invazije i metastaziranja preko njihove sposobnosti za degradaciju bazalnih membrana i proteina ekstracelularnog matriksa. Cilj rada bio je ispitati ekspresiju MMP-2, MMP-7 i MMP-9 u tumorskom tkivu i njihovu povezanost sa kliničkopatološkim karakteristikama bolesnika sa kolorektalnim karcinomom. Metode. Tkivni uzorci reseciranih kolorektalnih karcinoma i opkružujuće normalno tkivo 82 bolesnika sa kolorektralnim karcinomom bili su imunohistohemijski obojeni za MMP-2, MMP-7 i MMP-9. Rezultati imunohistohemijske ekspresije MMPs korelirani su sa pojedinim kliničkim i patološkim parametrima. Rezultati. Imunohistohemijska ekspresija MMP-2 bila je mnogo češća kod bolesnika sa većim preoperatvinim nivoima CEA u serumu (p = 0.047), predoperativnim nivoima MMP-2 (p = 0.018) i MMP-9 (p = 0.036) u serumu, kod bolesnika sa metastazama u limfnim žlezdama (p = 0.018) i sa uznapredovalim stadijumom bolesti (p = 0.046). Ekspresija MMP-7 bila je mnogo češća kod bolesnika sa povišenim preoperativnim serumskim nivoima CEA (p = 0.012), MMP-7 (p = 0.036) i MMP-9 (p = 0.023) i kod bolesnika sa dubokom invazijom neoplazme (p = 0.027). Ćelijska ekspresija MMP-9 bila je u pozitivnoj korelaciji sa povišenim preoperativnim serumskim nivoima CEA (p = 0.013), MMP-2 (p = 0.012), MMP-9 (p = 0.018) i sa dubinom invazije kolorektalnog karcinoma, tj. parametra T (p = 0.027). Zaključak. Imunohistohemijska ekspresija MMPs korisni je indikator razvoja i napredovanja bolesti kod bolesnika sa kolorektalnim karcinomom.

Reference

Ferlay J, Parkin DM, Steliarova-Fiocher E. Estimates of cancer in-cidence and mortality in Europe in 2008. Eur J Cancer 2010; 46(4): 765−81.

Sun X, Zhang H. Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infil-tration, MMP and PINCH in colorectal carcinomas. Molecular Cancer 2006; 5(1): 43.

Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clinl Oncol 2009; 27(31): 5287−97.

Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol 1997; 15(8−9): 535−41.

Hong SW, Kang YK, Lee B, Lee WY, Jang YG, Paik IW, et al. Matrix metalloproteinase-2 and -7 expression in colorectal cancer. J Korean Soc Coloproctol 2011; 27(3): 133−9.

Herszényi L, Hritz I, Lakatos G, Varga MZ, Tulassay Z. The be-havior of matrix metalloproteinases and their inhibitors in co-lorectal cancer. Int J Mol Sci 2012; 13(10): 13240−63.

Yang B, Su K, Gao J, Rao Z. Expression and Prognostic Value of Matrix Metalloproteinase-7 in Colorectal Cancer. Asian Pa-cific J Cancer Prev 2012; 13(3): 1049−52.

Leeman MF, Curran S, Murray GI. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 2003; 201(4): 528−34.

Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274(31): 21491−4.

Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996; 56(1): 190−6.

Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of Matrix Metalloproteinase-7 (Matrilysin) in Human Cancer In-vasion, Apoptosis, Growth, and Angiogenesis. Exp Biol Med J 2006; 231(1): 20−7.

Pesta M, Topolcan O, Holubec L, Rupert K, Cerna M, Holubec SL, et al. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples. Anticancer Res 2007; 27(4A): 1863−7.

Bendardaf R, Lamlum H, Pyrhönen S. Prognostic and predictive molecular markers in colorectal carcinoma. Anticancer Res 2004; 24(4): 2519−30.

Vihinen P, Kähäri V. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. International jour-nal of cancer. Int J Cancer 2002; 99(2): 157−66.

Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. Postgrad Med J 2008; 84(994): 403−11.

O'Jessica B, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edi-tion staging. J Natl Cancer Inst 2004; 96(19): 1420−5.

Ishida H, Murata N, Tada M, Okada N, Hashimoto D, Kubota S, et al. Determining the Levels of Matrix Metalloproteinase-9 in Portal and Peripheral Blood is Useful for Predicting Liver Me-tastasis of Colorectal Cancer. Jpn J Clin Oncol 2003; 33(4): 186−91.

Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Can-cer Invest 2005; 23(4): 338−51.

Mroczko B, Groblewska M, Okulczyk B, Kedra B, Szmitkowski M. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. Int J Colorectal Dis 2010; 25(10): 1177−84.

Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Takemiya S, Yanoma S, et al. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carci-noma. Br J Surg 2001; 88(12): 1596−601.

Illemann M. Histological Studies of Extracellular Matrix De-grading Proteases in Primary Colon Adenocarcinomas and Their Liver Metastases [dissertation]. Copenhagen: University of Copenhagen; 2008.

Pasternak B. Towards surgical use of matrix metalloproteinase biology [dissertation]. Linköping: Linköping University; 2008.

Liotta LA, Rao CN, Barsky SH. Tumor invasion and the ex-tracellular matrix. Lab. Invest 1983; 49(6): 636−49.

Tryggvason K. The laminin family. Curr Opin. Cell Biol 1993; 5(5): 877−82.

Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, et al. Stromal expression of 72 kda type IV col-lagenase (MMP-2) and TIMP-2 mRNAs in colorectal neopla-sia. Am J Pathol 1992; 141(2): 389−96.

Poulsom R, Hanby AM, Pignatelli M, Jeffery RE, Longcroft JM, Rogers L, et al. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol 1993; 46(5): 429−36.

Maatta M. Role of basement membranes and their break-down in human carcinomas. A study by in situ hybridization and immunohistochemistry of the expression of laminin chains, matrix metalloproteinases (MMPs) and their tissue inhibitors of metalloproteinases [dissertation]. Oulu: University of Oulu; 2000.

Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJ. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer 1998; 78(11): 1495−502.

Tutton MG, George ML, Eccles SA, Burton S, Swift IR, Abulafi MA. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. International journal of cancer. Int J Cancer 2003; 107(4): 541−50.

Ruokolainen H. The Prognostic Role of Matrix Metallopro-teinase-2 and -9 (MMP-2, MMP-9) and their Tissue Inhibitors -1 and -2 (TIMP-1, TIMP-2) in Head and Neck Squamous cell Carcinoma [dissertation]. Oulu: University of Oulu; 2005.

Dragutinović VV, Radonjić NV, Petronijević ND, Tatić SB, Dimitri-jević IB, Radovanović NS, et al. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in preoperative serum as independ-ent prognostic markers in patients with colorectal cancer. Mol Cell Biochem 2011; 355(1−2): 173−8.

Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Al-mendro V, et al. Serum matrix metalloproteinase 7 levels identi-fies poor prognosis advanced colorectal cancer patients. Inter-national journal of cancer. Int J Cancer 2007; 121(5): 1066−71.

Kim TS, Kim YB. Correlation between expression of matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9) and angiogenesis in colorectal adenocarcinoma. J. Korean Med Sci 1999; 14(3): 263−70.

Li B, Zhao P, Liu S, Yu Y, Han M, Wen J. Matrix metallopro-teinase-2 and tissue inhibitor of metallo-proteinase-2 in colo-rectal carcinoma invasion and metastasis. World J Gastroen-terol 2005; 11(20): 3046−50.

Cho YR, Kwon H, Suh S, Lee JH, Kim S, Choi H, et al. Expres-sions of matrix metalloproteinase-7 and -9 and their prognos-tic significances in rectal cancer. Cancer Res Treat 2005; 37(6): 354−9.

Schwandner O, Schlamp A, Broll R, Bruch HP. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. Int J Colorectal Dis 2007; 22(2): 127−36

Objavljeno
2015/04/21
Broj časopisa
Vol. 71 Br. 1 (2014)
Rubrika
Originalni članak